Vaxcyte to Speak at 2024 Cantor Global Healthcare Conference

Vaxcyte, Inc., situated in San Carlos, California, and listed on Nasdaq under the symbol PCVX, is pioneering the development of innovative vaccines to combat bacterial diseases. The company, which operates at the clinical stage, has announced its participation in a fireside chat at the 2024 Cantor Global Healthcare Conference scheduled for Wednesday, September 18, at 10:20 a.m. ET / 7:20 a.m. PT. The discussion will be accessible via live webcast on the company’s website, with a replay available for approximately 30 days post-conference.

Vaxcyte specializes in creating high-fidelity vaccines aimed at preventing or treating bacterial infectious diseases. Their pipeline includes broad-spectrum conjugate and novel protein vaccines. One of their leading candidates, VAX-31, is a 31-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) poised for Phase 3 trials. It is designed to prevent invasive pneumococcal disease (IPD) in both adults and infants and stands as the most comprehensive PCV candidate currently in clinical trials. Additionally, Vaxcyte is developing VAX-24, a 24-valent PCV candidate intended to cover a broader range of serotypes than any existing infant PCV. VAX-24 is currently undergoing evaluation in a Phase 2 infant study.

Both VAX-31 and VAX-24 aim to surpass the efficacy of current standard-of-care PCVs by addressing serotypes that are major contributors to IPD and are linked with high mortality rates, antibiotic resistance, and meningitis. At the same time, these candidates maintain effective coverage of previously circulating strains, ensuring continued protection through vaccination programs.

Vaxcyte is revolutionizing the production of complex vaccines using modern synthetic techniques. This includes advanced chemistry and the XpressCF™ cell-free protein synthesis platform, licensed exclusively from Sutro Biopharma, Inc. Unlike traditional cell-based methods, Vaxcyte’s system facilitates the efficient creation of difficult-to-produce proteins and antigens, expediting the delivery of high-fidelity vaccines with superior immunological benefits.

The company’s pipeline extends beyond pneumococcal vaccines. VAX-A1 is in development as a prophylactic vaccine to prevent Group A Strep infections. VAX-PG is a therapeutic vaccine candidate designed to halt or slow the progression of periodontal disease. Additionally, VAX-GI is in development to prevent infections caused by Shigella. Vaxcyte’s mission is to eliminate or manage invasive bacterial infections that can lead to severe and costly health issues if not addressed.

With its commitment to advancing vaccine technology and addressing unmet medical needs, Vaxcyte is positioned at the forefront of combating bacterial diseases through innovative solutions that enhance public health outcomes.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!